Center for Therapeutic Innovation (CTI)
UCSF and Pfizer’s Center for Therapeutic Innovation (CTI) announce a
CTI Request for Proposals
2 page pre-proposals due October 22nd, 2012
CTI enables translational medicine by working in a highly collaborative team with UCSF investigators to develop biologic therapeutics. Research initiates with a UCSF validated target and the team will jointly develop a therapeutic and take through Phase I proof of concept studies.
Focus on protein therapeutics (e.g., monoclonal antibodies, antibody variants, recombinant proteins, Fc-fusion, pegylated proteins, antibody and protein conjugates, bi-specific antibodies and peptides)
Co-location of scientists, technology and drug development expertise
Collaborative use of Pfizer’s proprietary drug discovery tools and technologies
Support for IND- & clinical-enabling functions (toxicology, regulatory, etc.)
Success-based funding/financial incentives (milestone & royalty payments)
For the 2012 RFP, CTI is focused on targets in three main disease areas:
Autoimmunity (especially Systemic Lupus Erythematosus / Lupus Nephritis)
Mechanisms that prevent the underlying dysregulation of B- and T- cells
Target or interrupt inducers of persistent immune activation/inflammation
Inhibition or modulation of inflammatory processes involved in flares (renal, synovial or cutaneous); regulate handling and clearance of apoptotic bodies, or other pro-inflammatory cellular debris
Modulate target organ susceptibility to immune-mediated damage or promote immune homeostasis and immunoregulation (i.e., functional tolerance).
Renal Disease (Kidney Injury/Lupus Glomerulonephritis, IgA Nephropathy)
Mechanisms that block intrarenal inflammation, regulate leukocyte-endothelial cell interactions, prevent tubular atrophy and interstitial injury, or inhibit specific components of the immune response related to renal damage
Approaches that are aimed at promoting responses leading to improved renal function
Cardiovascular (Congestive Heart Failure, Post-Myocardial Infarction and Acute Coronary Syndrome)
Mechanisms may include those that impact extracellular matrix turnover, fibrosis, restore cardiac tissue & function, apoptosis & proliferation, cardioprotection and neovascularization.
Novel mechanisms that impact endothelial repair (beyond standard of care) to reduce CV events post–ACS such as plaque stabilization and dissolution, mast cell & macrophage regulation
A two-page, non-confidential pre-proposal in the required format must be submitted to Stephanie Robertson email@example.com on or before October 22, 2012. A CTI Steering Committee comprised of Pfizer CTI scientists and UCSF Investigators will review and select the most promising proposals for further development. UCSF scientists whose pre-proposals are selected for further consideration will be invited to submit a full proposal that may be written in collaboration with Pfizer scientists, and will be evaluated for funding by the CTI Steering Committee.